CL2016001364A1 - Moduladores de ror gamma (rory) - Google Patents
Moduladores de ror gamma (rory)Info
- Publication number
- CL2016001364A1 CL2016001364A1 CL2016001364A CL2016001364A CL2016001364A1 CL 2016001364 A1 CL2016001364 A1 CL 2016001364A1 CL 2016001364 A CL2016001364 A CL 2016001364A CL 2016001364 A CL2016001364 A CL 2016001364A CL 2016001364 A1 CL2016001364 A1 CL 2016001364A1
- Authority
- CL
- Chile
- Prior art keywords
- rory
- ror gamma
- gamma modulators
- ror
- modulators
- Prior art date
Links
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195813 | 2013-12-05 | ||
| EP14183274 | 2014-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001364A1 true CL2016001364A1 (es) | 2016-12-02 |
Family
ID=52021176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001364A CL2016001364A1 (es) | 2013-12-05 | 2016-06-03 | Moduladores de ror gamma (rory) |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9738600B2 (OSRAM) |
| EP (1) | EP3077372B8 (OSRAM) |
| JP (1) | JP6461960B2 (OSRAM) |
| KR (1) | KR102251128B1 (OSRAM) |
| CN (1) | CN105980353B (OSRAM) |
| AU (1) | AU2014359324B2 (OSRAM) |
| CA (1) | CA2932483C (OSRAM) |
| CL (1) | CL2016001364A1 (OSRAM) |
| CR (1) | CR20160303A (OSRAM) |
| DK (1) | DK3077372T3 (OSRAM) |
| DO (1) | DOP2016000125A (OSRAM) |
| EA (1) | EA030393B1 (OSRAM) |
| ES (1) | ES2722409T3 (OSRAM) |
| HR (1) | HRP20190483T1 (OSRAM) |
| HU (1) | HUE043258T2 (OSRAM) |
| IL (1) | IL246018B (OSRAM) |
| LT (1) | LT3077372T (OSRAM) |
| MX (1) | MX368721B (OSRAM) |
| MY (1) | MY179106A (OSRAM) |
| PE (1) | PE20160891A1 (OSRAM) |
| PH (1) | PH12016501066A1 (OSRAM) |
| PL (1) | PL3077372T3 (OSRAM) |
| PT (1) | PT3077372T (OSRAM) |
| RS (1) | RS58650B1 (OSRAM) |
| SI (1) | SI3077372T1 (OSRAM) |
| TN (1) | TN2016000224A1 (OSRAM) |
| UA (1) | UA117941C2 (OSRAM) |
| WO (1) | WO2015082533A1 (OSRAM) |
| ZA (1) | ZA201604043B (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145371A1 (en) * | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
| AP2016009542A0 (en) * | 2014-04-16 | 2016-11-30 | Glenmark Pharmaceuticals Sa | Aryl and heteroaryl ether compounds as ror gamma modulators |
| EP3212642B1 (en) | 2014-10-30 | 2019-10-30 | Janssen Pharmaceutica NV | Amide substituted thiazoles as modulators of rorgammat |
| TWI667230B (zh) | 2014-10-30 | 2019-08-01 | 比利時商健生藥品公司 | 用作ＲＯＲγｔ調節劑之三氟甲基醇 |
| LT3212641T (lt) | 2014-10-30 | 2019-02-11 | Janssen Pharmaceutica Nv | Tiazolai, kaip roryt moduliatoriai |
| CN107614062A (zh) | 2015-03-12 | 2018-01-19 | 加利福尼亚大学董事会 | 用RORγ抑制剂治疗癌症的方法 |
| CU24487B1 (es) | 2015-05-15 | 2020-11-30 | Aurigene Discovery Tech Ltd | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror |
| WO2016193894A1 (en) * | 2015-05-29 | 2016-12-08 | Glenmark Pharmaceuticals S.A. | Treatment of respiratory disorders using ror- gamma inhibitors |
| EP3101008A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101005A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| WO2017010399A1 (ja) * | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物 |
| TWI728017B (zh) | 2015-12-15 | 2021-05-21 | 瑞典商阿斯特捷利康公司 | 異吲哚化合物、包含其之醫藥組成物及其用途 |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| WO2018011747A1 (en) * | 2016-07-14 | 2018-01-18 | Cadila Healthcare Limited | Polycyclic compounds as ror-gamma modulators |
| EP3481809A1 (en) | 2016-07-14 | 2019-05-15 | Cadila Healthcare Limited | Cyclopropyl derivatives as ror-gamma modulators |
| UY37507A (es) | 2016-12-05 | 2018-06-29 | Lead Pharma Holding Bv | Moduladores de ror gamma (ror¿) |
| WO2018116285A1 (en) * | 2016-12-23 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Substituted morpholine derivatives as ror gamma modulators |
| EP3638661A1 (en) | 2017-06-14 | 2020-04-22 | Astrazeneca AB | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
| EP3806958B1 (en) | 2018-06-18 | 2022-09-07 | Janssen Pharmaceutica NV | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
| CA3103929A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
| ES2925473T3 (es) | 2018-06-18 | 2022-10-18 | Janssen Pharmaceutica Nv | Pirazoles de piridinilo como moduladores de RORyt |
| CN112334450A (zh) | 2018-06-18 | 2021-02-05 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基和吡啶基取代的咪唑 |
| TWI839461B (zh) | 2019-02-06 | 2024-04-21 | 美商戴斯阿爾法股份有限公司 | Il-17a調節物及其用途 |
| JP7566889B2 (ja) | 2019-09-16 | 2024-10-15 | ダイス・アルファ・インコーポレイテッド | Ｉｌ－１７ａモジュレーターおよびその使用 |
| CN112759541B (zh) * | 2019-10-21 | 2023-03-17 | 复旦大学 | 类吲哚衍生物及其用途 |
| CN113072521B (zh) * | 2020-01-06 | 2024-04-05 | 广东东阳光药业股份有限公司 | RORγt抑制剂及其在药物中的应用 |
| TW202136238A (zh) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
| CN114075139B (zh) * | 2020-08-14 | 2025-09-26 | 广东东阳光药业股份有限公司 | 五元杂芳环类化合物及其在药物中的应用 |
| CN120383557A (zh) * | 2024-01-26 | 2025-07-29 | 上海医药集团股份有限公司 | 一种乙磺酰苯基乙酰胺类化合物的晶型、其制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| WO2012027965A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| CN104884448A (zh) * | 2012-10-16 | 2015-09-02 | 詹森药业有限公司 | Rorγt的杂芳基连接的喹啉基调节剂 |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| BR112015023571A2 (pt) * | 2013-03-15 | 2017-07-18 | Hoffmann La Roche | derivados de sulfamato e sulfamida de arila como moduladores rorc |
| EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
-
2014
- 2014-12-03 AU AU2014359324A patent/AU2014359324B2/en not_active Ceased
- 2014-12-03 ES ES14809794T patent/ES2722409T3/es active Active
- 2014-12-03 TN TN2016000224A patent/TN2016000224A1/en unknown
- 2014-12-03 SI SI201431174T patent/SI3077372T1/sl unknown
- 2014-12-03 CR CR20160303A patent/CR20160303A/es unknown
- 2014-12-03 DK DK14809794.2T patent/DK3077372T3/en active
- 2014-12-03 KR KR1020167017849A patent/KR102251128B1/ko not_active Expired - Fee Related
- 2014-12-03 HU HUE14809794A patent/HUE043258T2/hu unknown
- 2014-12-03 PT PT14809794T patent/PT3077372T/pt unknown
- 2014-12-03 WO PCT/EP2014/076390 patent/WO2015082533A1/en not_active Ceased
- 2014-12-03 UA UAA201607189A patent/UA117941C2/uk unknown
- 2014-12-03 MX MX2016007275A patent/MX368721B/es active IP Right Grant
- 2014-12-03 JP JP2016536162A patent/JP6461960B2/ja not_active Expired - Fee Related
- 2014-12-03 PE PE2016000733A patent/PE20160891A1/es unknown
- 2014-12-03 CA CA2932483A patent/CA2932483C/en active Active
- 2014-12-03 HR HRP20190483TT patent/HRP20190483T1/hr unknown
- 2014-12-03 CN CN201480074695.6A patent/CN105980353B/zh not_active Expired - Fee Related
- 2014-12-03 US US15/102,098 patent/US9738600B2/en not_active Expired - Fee Related
- 2014-12-03 RS RS20190494A patent/RS58650B1/sr unknown
- 2014-12-03 PL PL14809794T patent/PL3077372T3/pl unknown
- 2014-12-03 EP EP14809794.2A patent/EP3077372B8/en active Active
- 2014-12-03 LT LTEP14809794.2T patent/LT3077372T/lt unknown
- 2014-12-03 EA EA201691173A patent/EA030393B1/ru not_active IP Right Cessation
- 2014-12-03 MY MYPI2016702008A patent/MY179106A/en unknown
-
2016
- 2016-06-03 DO DO2016000125A patent/DOP2016000125A/es unknown
- 2016-06-03 CL CL2016001364A patent/CL2016001364A1/es unknown
- 2016-06-03 PH PH12016501066A patent/PH12016501066A1/en unknown
- 2016-06-05 IL IL246018A patent/IL246018B/en active IP Right Grant
- 2016-06-14 ZA ZA2016/04043A patent/ZA201604043B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CL2018000978A1 (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| DOP2016000125A (es) | MODULADORES DE ROR GAMMA (RORy) | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| CL2016000106A1 (es) | Sulfonamidas como moduladores de canales de sodio. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
| PH12016502167A1 (en) | Hdl theraphy markers | |
| BR112016019592A8 (pt) | Composto, uso de um composto, e, composição farmacêutica | |
| CL2015003019A1 (es) | Derivados biaromáticos antibacterianos | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| MX2016015630A (es) | Nuevos compuestos. | |
| ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| MX374728B (es) | MODULADORES DE ROR GAMMA (RORy). | |
| CL2016002422A1 (es) | Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas. | |
| CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos |